University spinouts and the commercialisation gap
Universities produce world-class research, but turning it into companies remains hard in many countries. Here is what the evidence says about the commercialisation gap and how different regions are trying to close it.
Key points
- The commercialisation gap describes the difficulty of turning university research into companies and products.
- The Draghi report found Europe struggles to translate innovation into commercialisation and scale.
- Deep tech took 36% of European venture dollars in 2025, up from 19% in 2021, according to Atomico.
- Clear IP terms, experienced leadership, patient capital and early customer engagement help spinouts succeed.
Countries invest heavily in university research. A growing question for policy makers is how much of that research becomes products, companies and jobs. The gap between research excellence and commercial outcomes is often called the commercialisation gap, and many countries, including Australia, are trying to close it.
The problem in brief
Universities are designed to create and share knowledge. Turning a discovery into a company requires different skills: identifying a market, protecting intellectual property, raising capital, building a team and selling to customers. Researchers may lack the time, incentives or experience to do this, and university processes for licensing technology can be slow.
What Europe’s experience shows
The Draghi report on European competitiveness, delivered to the European Commission in September 2024, described the problem clearly. It argued that Europe is failing to translate innovation into commercialisation, and that innovative companies trying to scale are held back by regulation and limited access to growth capital.
At the same time, European venture investment has shifted toward science-based companies. Atomico’s State of European Tech 2025 report found that 36% of European venture dollars went into deep tech companies in 2025, up from 19% in 2021. Many of these companies have roots in university research.
Japan’s policy push
Japan’s Startup Development Five-Year Plan, released in November 2022, includes measures to support university spinouts, including funding through the Japan Science and Technology Agency and entrepreneurship education. The plan treats universities as a key source of new companies in an economy where large corporations have traditionally dominated innovation.
Australia’s position
Australia has strong research universities and a history of important discoveries, but commercialisation has long been identified as a weakness. Policy tools include the Research and Development Tax Incentive, programs to connect researchers with industry and university-linked venture funds and accelerators. The early stage innovation company tax incentives also award points under their innovation test for factors associated with research commercialisation.
Australia’s Productivity Commission has linked slower business dynamism, including fewer new employing firms, to weak productivity growth. University spinouts are one source of the new, innovative firms that can help.
What helps spinouts succeed
Research and practice point to several factors:
- Clear, fair intellectual property terms. Simple, standardised licensing reduces negotiation time and makes companies easier to fund.
- Experienced business leadership. Pairing researchers with entrepreneurs who have built companies.
- Patient capital. Deep tech companies often need years of development before significant revenue.
- Early customer engagement. Testing whether industry needs the technology before investing heavily.
- Supportive university culture. Recognising commercialisation in academic careers and allowing researchers time to work on spinouts.
The United States as a benchmark
The United States is often cited as a benchmark, with universities such as Stanford and MIT producing many successful companies. Factors include a long-standing legal framework for university ownership of federally funded inventions, deep pools of venture capital near major universities and a culture that rewards entrepreneurship. But even in the United States, most university research does not become a company, and outcomes vary widely across institutions.
Measuring commercialisation
Measuring commercialisation is difficult. Common indicators include the number of patents and licences, spinout companies formed, capital raised by those companies and income from licensing. Each has limitations. Patent counts say little about commercial value, and spinout numbers can be inflated by companies that never trade. More useful measures look at outcomes over time, such as employment and revenue in spinout companies, follow-on investment and products reaching the market. Policy makers in several countries are working to improve these measures so that support can be directed to what works.
Frequently asked questions
Who owns intellectual property created at a university?
It depends on the university’s policies and funding arrangements. In many cases the university owns it and licenses it to a spinout in exchange for equity or royalties.
Why do spinouts need patient capital?
Many are built on new science that takes years to develop into products, so revenue may come much later than for typical software startups.
Can researchers stay at the university while running a spinout?
Many universities allow this, often with agreed time commitments and conflict-of-interest arrangements. Policies vary by institution.
References
- European Commission: The future of European competitiveness (Draghi report)
- Sifted: 10 key findings from Atomico’s State of European Tech report
- Government of Japan: Startup Development Five-year Plan (2022)
- Productivity Commission: Competition, dynamism and productivity (2023)
- Australian Taxation Office: Tax incentives for innovation
Related reading
General information only. This article reflects the author’s views at the time of writing. It does not take into account your objectives, financial situation or needs, and it is not financial, legal or tax advice or a recommendation to invest. Figures are from the sources named and may change. See our terms of use.